These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
253 related articles for article (PubMed ID: 25210627)
1. Anti-VEGF Cancer Therapy in Nephrology Practice. Izzedine H Int J Nephrol; 2014; 2014():143426. PubMed ID: 25210627 [TBL] [Abstract][Full Text] [Related]
2. Kidney diseases associated with anti-vascular endothelial growth factor (VEGF): an 8-year observational study at a single center. Izzedine H; Escudier B; Lhomme C; Pautier P; Rouvier P; Gueutin V; Baumelou A; Derosa L; Bahleda R; Hollebecque A; Sahali D; Soria JC Medicine (Baltimore); 2014 Nov; 93(24):333-339. PubMed ID: 25500702 [TBL] [Abstract][Full Text] [Related]
3. Intravitreal Antivascular Endothelial Growth Factor Therapy May Induce Proteinuria and Antibody Mediated Injury in Renal Allografts. Cheungpasitporn W; Chebib FT; Cornell LD; Brodin ML; Nasr SH; Schinstock CA; Stegall MD; Amer H Transplantation; 2015 Nov; 99(11):2382-6. PubMed ID: 25905984 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological spectrum of kidney diseases in cancer patients treated with vascular endothelial growth factor inhibitors: a report of 5 cases and review of literature. Usui J; Glezerman IG; Salvatore SP; Chandran CB; Flombaum CD; Seshan SV Hum Pathol; 2014 Sep; 45(9):1918-27. PubMed ID: 25087655 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal Injection of Anti-VEGF Antibody Induces Glomerular Endothelial Cells Injury. Touzani F; Geers C; Pozdzik A Case Rep Nephrol; 2019; 2019():2919080. PubMed ID: 31934470 [TBL] [Abstract][Full Text] [Related]
6. TAFRO syndrome as a cause of glomerular microangiopathy: a case report and literature review. Nagayama Y; Yamano M; Yagame M; Nariyama T; Takahashi M; Kawamoto M; Matsui K BMC Nephrol; 2019 Oct; 20(1):375. PubMed ID: 31623576 [TBL] [Abstract][Full Text] [Related]
7. Characteristic morphological changes in anti-VEGF therapy-induced glomerular microangiopathy. Pfister F; Amann K; Daniel C; Klewer M; Büttner A; Büttner-Herold M Histopathology; 2018 Dec; 73(6):990-1001. PubMed ID: 30014486 [TBL] [Abstract][Full Text] [Related]
8. VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experience. Ozawa M; Ohtani H; Komatsuda A; Wakui H; Takahashi N Clin Exp Nephrol; 2021 Nov; 25(11):1193-1202. PubMed ID: 34115234 [TBL] [Abstract][Full Text] [Related]
10. Thrombotic Microangiopathy and Acute Kidney Injury Induced After Intravitreal Injection of Vascular Endothelial Growth Factor Inhibitors VEGF Blockade-Related TMA After Intravitreal Use. Hanna RM; Tran NT; Patel SS; Hou J; Jhaveri KD; Parikh R; Selamet U; Ghobry L; Wassef O; Barsoum M; Bijol V; Kalantar-Zadeh K; Pai A; Amin A; Kupperman B; Kurtz IB Front Med (Lausanne); 2020; 7():579603. PubMed ID: 33117836 [TBL] [Abstract][Full Text] [Related]
11. Bevacizumab-associated glomerular microangiopathy that occurred after postoperative chemotherapy for ovarian cancer. Morimoto M; Arai T; Matsuura M; Ono Y CEN Case Rep; 2021 Feb; 10(1):6-11. PubMed ID: 32642991 [TBL] [Abstract][Full Text] [Related]
12. Kidney injury during VEGF inhibitor therapy. den Deurwaarder ES; Desar IM; Steenbergen EJ; Mulders PF; Wetzels JF; van Herpen CM Neth J Med; 2012 Aug; 70(6):267-71. PubMed ID: 22859418 [TBL] [Abstract][Full Text] [Related]
13. Proteinuria and hypertension in patients treated with inhibitors of the VEGF signalling pathway--incidence, mechanisms and management. Tesařová P; Tesař V Folia Biol (Praha); 2013; 59(1):15-25. PubMed ID: 23537524 [TBL] [Abstract][Full Text] [Related]
14. Pathologic Correlation with Renal Dysfunction after Intravitreal Injections of Vascular Endothelial Growth Factor Antagonists. Zhang PL; Raza S; Li W; Kanaan HD Ann Clin Lab Sci; 2021 Nov; 51(6):875-882. PubMed ID: 34921042 [TBL] [Abstract][Full Text] [Related]